Characterization of Immunoregulatory Pathway Activation for Functional Diagnosis and Optimization of Immunotherapy in Lung Cancer

• Grant number: 25/02792-9
• Support Opportunities: Regular Research Grants
• Start date: June 01, 2025
• End date: May 31, 2027
• Field of knowledge: Health Sciences - Medicine - Surgery
• Mobility Program: SPRINT - Projetos de pesquisa - Mobilidade
• Principal Investigator: Lidia Maria Rebolho Batista Arantes
• Grantee: Lidia Maria Rebolho Batista Arantes
• Principal researcher abroad: Patrick Micke
• Institution abroad: Uppsala University (UU), Sweden
• Host Institution: Hospital do Câncer de Barretos. Fundação Pio XII (FP). Barretos , SP, Brazil
• Associated research grant: 19/07111-9 - Immune-checkpoint inhibitors: immunophenotyping and clinical outcome to predict response at Barretos Cancer Hospital, AP.JP

Abstract

Lung cancer causes 1.8 million deaths annually, representing the highest cancer mortality rate, with 85% of patients falling under non-small cell lung cancer (NSCLC). Immunotherapy targeting immune checkpoint inhibitors (ICI) has shown significant advances, employing monoclonal antibodies to modulate co-stimulatory and co-inhibitory signals crucial for immune tolerance maintenance. Despite its progress, immunotherapy in NSCLC still faces challenges that must be overcome to benefit a larger patient population. Characterizing the immune landscape of the tumor microenvironment (TME) is crucial for advancing and expanding immunotherapy. Identifying immune markers capable of distinguishing responders from non-responders to ICI therapy in NSCLC patients is essential. Through multiplex immunohistochemistry with lineage markers (CD4, CD8, CD20, FoxP3, CD168, CD168, CD38), checkpoint inhibitors (PD1, PD-L1, LAG3, LAM3, CD40, ICOS) as well as potentially relevant signal pathways (pSMAD, pSTAT3, activated YAP), this study aims to evaluate complex cellular interactions and spatial organization in the TME of forty NSCLC patients treated with anti-PD1 and/or anti-PD-L1 ICIs. Additionally, proximity ligation assays (PLA) will investigate subcellular interactions among key immune checkpoints including PD1-PD-L1, TIGIT-CD155, CTLA4-B7, TIM3-GAL9 and LAG3-MHCII. The study hypothesizes that insights into immune infiltrate distribution and its correlation with treatment response will reveal predictive biomarkers for patient stratification. Through thorough analysis and interpretation, this research aims to advance understanding of the NSCLC TME, potentially guiding improved therapeutic strategies tailored to individual patient profiles. (AU)